CDKN2A and renal cell carcinoma: The pooled OR from four studies suggested that p16INK4A promoter methylation was not significantly correlated with gender in RCC (OR = 0.66, 95% CI = 0.31-1.38, P = 0.266), including in 201 males and 91 females (Table 4).